Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
85 participants
INTERVENTIONAL
2025-11-24
2027-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
mpUS imaging is a type of ultrasound imaging that combines different ultrasound methods and analysis to create a more detailed and accurate assessment of tissue. Standard ultrasound provides a basic image of tissue structure, but mpUS imaging can also show blood vessels, blood flow, and detailed tissue structure (microstructure). The researchers think that mpUS may be a better way for evaluating cancer because it combines different ultrasound methods to assess tissue.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ultrasound-Guided Photoacoustic Imaging for the Detection of Metastases in Inguinal Lymph Nodes
NCT04185337
Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast
NCT00671411
3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer
NCT05704283
Prospective Multi-center, Single Blinded, Randomized, Controlled Trial of EUS-FNB and EUS-FNA on Solid Occupying Lesion
NCT02327065
EUS- and US- Guided Biopsy for Pancreatic Lesion
NCT07138976
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Multiparametric endoscopic (mpEUS) imaging of patients at high-risk for pancreatic cancer
Subjects will undergo add-on mpEUS imaging during their standard of care EUS imaging and will add up to approximately 15 minutes of added scan time.
Multiparametric ultrasound (mpUS) imaging
Patients will undergo the added research sequences at any point during their standard of care ultrasound scans, adding up to approximately 15 minutes of added scan time. The only non-routine measurements will be the research ultrasound data.
Multiparametric endoscopic (mpEUS) imaging of patients with pancreatic ductal adenocarcinoma
Subjects will undergo add-on mpEUS imaging during their standard EUS procedure and will add up to approximately 15 minutes of added scan time.
Multiparametric ultrasound (mpUS) imaging
Patients will undergo the added research sequences at any point during their standard of care ultrasound scans, adding up to approximately 15 minutes of added scan time. The only non-routine measurements will be the research ultrasound data.
Thyroid nodule assessment with multiparametric ultrasound (mpUS) imaging
Subjects will undergo add-on mpUS imaging at the beginning of their standard of care ultrasound procedure and will add up to approximately 5 minutes of added scan time.
Multiparametric ultrasound (mpUS) imaging
Patients will undergo the added research sequences at any point during their standard of care ultrasound scans, adding up to approximately 15 minutes of added scan time. The only non-routine measurements will be the research ultrasound data.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Multiparametric ultrasound (mpUS) imaging
Patients will undergo the added research sequences at any point during their standard of care ultrasound scans, adding up to approximately 15 minutes of added scan time. The only non-routine measurements will be the research ultrasound data.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Patient Group: those having standard endoscopic ultrasounds because they are at high risk of pancreatic cancer Participants enrolled into the Memorial Sloan Kettering Cancer Center Pancreatic Registry protocol (IRB#: 02-102) will be eligible for this study. Specifically, related individuals without pancreatic cancer who are at-risk for developing pancreatic cancer and meet all of the following criteria (family health history will be self-reported):
* 10 years younger than the earliest pancreatic cancer diagnosis in the family
* Be at least 50 years old
* Be at least 40 years old if diagnosed with FAMMM syndrome (CDKN2A/p16) or Hereditary Pancreatitis (PRSS1, SPINK1/PST1, CTRC, CPA1 or other candidate hereditary pancreatitis genes)
* Be at least 35 years old if diagnosed with Peutz-Jeghers syndrome (STK11 aka LKB1)
* Not pregnant and not Nursing
* Relatives at least 21 years old with other high-risk clinical criteria that warrants pancreatic cancer surveillance or follow-up as determined by the project leader (Dr. Vineet Rolston)
* Must agree to be contacted for follow-up
* Must satisfy at least one of the following 4 criteria:
1. Have at least two affected relatives who are a first-degree relative to each other, of whom at least one is a first degree relative to the individual OR have at least two affected first-degree relatives on the same side of the family.
2. Have at least one first- or second-degree affected relative and have germline genetic test results that confirm a likely pathogenic or pathogenic variant in at least one of the following genes:
1. APC (Familial Adenomatous Polyposis (FAP) and Attenuated FAP syndrome
2. BRCA1(Hereditary Breast and Ovarian Cancer Symptoms)
3. MLH1, MSH2, MSH6, PMS2, or EPCAM (Lynch Syndrome)
4. PALB2
5. TP53 (Li-Fraumeni Syndrome)
6. Other established pancreatic cancer predisposition gene per project leader's discretion
3. Have germline genetic test results that confirm a likely pathogenic or pathogenic variant in one or more of the following genes:
1. CDKN2A/p16 (Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM))
2. STK11 aka LKB1 (Peutz-Jeghers Syndrome)
3. PRSS1, SPINK1/PST1, CTRC, CPA1 or other candidate hereditary pancreatitis genes per project leader's discretion
4. ATM (ataxia telangiectasia mutated)
5. BRCA 2(Hereditary Breast and Ovarian Cancer Symptoms)
4. Relatives at least 21 years old with other high-risk clinical criteria that warrants pancreatic cancer surveillance or follow-up as determined the project leader (Dr. Vineet Rolston)
Cohort 2 - Multiparametric endoscopic ultrasound imaging (mpEUS) of patients with pancreatic ductal adenocarcinoma:
Patient Group: those with pancreatic cancer having endoscopic ultrasound-guided biopsies
Patients will be entered into the study if they meet the following criteria:
* Patients with pancreatic ductal adenocarcinoma
* Are undergoing endoscopic ultrasound-guided tissue core biopsy as part of their standard of care
* Not pregnant and not nursing
Cohort 3 - Thyroid nodule assessment with multiparametric ultrasound (mpUS) imaging:
Patient Group: those with a thyroid nodule that will be biopsied whether they have known cancer or not
* Are undergoing ultrasound-guided thyroid biopsy as part of their standard of care
* Not pregnant and not nursing
Healthy Volunteers will be entered into the study if they meet the following criteria:
* No known cancer diagnosis or thyroid nodules
* Age ≥ 18
* Able to understand and give informed consent
* Not pregnant and not nursing
Exclusion Criteria
* Unable to sign an informed consent for medical or other reasons; residents outside the continental United States
* Under 18 years of age
Cohort 3 -Thyroid nodule assessment with multiparametric ultrasound (mpUS) imaging
* Unable to sign an informed consent for medical or other reasons; residents outside the continental United States
* Under 18 years of age
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Memorial Sloan Kettering Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark T Burgess, MD
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Memorial Sloan Kettering Basking Ridge (Consent Only)
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Consent Only)
Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (Consent Only)
Montvale, New Jersey, United States
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
Commack, New York, United States
Memorial Sloan Kettering Westchester (Consent Only)
Harrison, New York, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States
Memorial Sloan Kettering Nassau (Consent Only)
Uniondale, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mark T Burgess, PhD
Role: primary
Mark T Burgess, PhD
Role: primary
Mark T Burgess, PhD
Role: primary
Mark T Burgess, PhD
Role: primary
Mark T Burgess, PhD
Role: primary
Mark T Burgess, PhD
Role: primary
Mark T Burgess, PhD
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Memorial Sloan Kettering Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
25-299
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.